Hanmi Pharm's Hypertension Treatment 'Amozaltan' Enters Chinese Market as 'Meiyaping'

Hanmi Pharmaceutical's hypertension treatment 'Amozaltan' is marketed in China under the product name 'Meiyaping (美?平)'

[Asia Economy Reporter Chunhee Lee] Hanmi Pharmaceutical's hypertension treatment drug ‘Amozantan’ will be launched nationwide in China this September under the product name ‘Meiyaping (美?平)’.

Hanmi Pharmaceutical Group's local Chinese subsidiary, Beijing Hanmi Pharmaceutical, announced on the 25th that it has decided on the official Chinese brand name for ‘Amozantan’ and will begin full-scale pre-marketing activities for its launch. Meiyaping means 'exceptionally lowers blood pressure and maintains it evenly.' Meiyaping received marketing approval from the China National Medical Products Administration (NMPA) in March.

According to the National Health Commission of China, the prevalence of hypertension among Chinese people has been rapidly increasing every year, currently estimated at 380 million people, or 32% of those aged 18 and over.

The domestic brand of Meiyaping, Amozantan, is a combination drug that combines the hypertension treatment ingredients ‘Amlodipine’ and ‘Losartan’. It is a prescription drug (ETC) that created a new trend of combination drugs in the Korean pharmaceutical market, which had been dominated by simple generics.

Following Amozantan, Hanmi Pharmaceutical consecutively launched the triple combination drugs 'Amozantan Plus' and 'Amozantan Q', and recently released the quadruple combination drug ‘Amozantan XQ’ that can comprehensively treat dyslipidemia as well. The ‘Amozantan family’ configured in this way has surpassed cumulative prescription sales of 1 trillion won since the launch of Amozantan in 2009.

In terms of efficacy, 14 clinical studies, including a ‘large-scale patient data (real-world data) study’ conducted over 10 years from 2009 to 2019 involving 15,538 Koreans, confirmed high treatment effects and improved medication adherence, and these studies have been published in SCI(E)-level international journals, securing scientific data.

Beijing Hanmi Pharmaceutical expects to achieve meaningful results by challenging the Chinese hypertension treatment market based on the successful marketing case in Korea.

Lim Haeryong, General Manager of Beijing Hanmi Pharmaceutical, said, “Currently, the Chinese hypertension market is highly competitive due to the entry of various pharmaceutical companies and several entry barriers such as the Chinese government’s drug price reduction policy. However, we will do our best to gradually increase market share in China by utilizing Beijing Hanmi Pharmaceutical’s local marketing know-how and Hanmi Pharmaceutical’s Amozantan success case, and continue the Amozantan success story in China.”

This content was produced with the assistance of AI translation services.